↓ Skip to main content

The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts

Overview of attention for article published in Journal of Translational Medicine, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts
Published in
Journal of Translational Medicine, June 2015
DOI 10.1186/s12967-015-0555-4
Pubmed ID
Authors

Anne-France le Rolle, Thang K Chiu, Michael Fara, Jinru Shia, Zhaoshi Zeng, Martin R Weiser, Philip B Paty, Vi K Chiu

Abstract

Clinical therapy for metastatic colorectal cancer (CRC) remains limited, especially when the tumor harbors a KRAS mutation. This study aimed to identify prognostic biomarkers in CRC that are accessible for therapeutic inhibition. Conditioned media from human CRC epithelial cells and myofibroblasts were screened by cytokine arrays for tumorigenic factors. The protein and mRNA expressions of these factors were determined by immunohistochemistry and gene microarrays in human CRC tissues. Prognostic biomarkers were determined by correlation of mRNA expression to overall survival in stage IV CRC patients. Inhibition of CXCL1 was performed with specific neutralizing antibody and lentiviral shRNAs. Malignant growth was assessed by soft agar growth assays and xenograft tumor growth in immunocompromised mice. CXCL1 was highly secreted by KRAS mutant human CRC cells and myofibroblasts in a complementary adaptive response to serum deprivation. Elevated CXCL1 level promoted anchorage-independent growth of murine fibroblasts and human CRC cells. Inhibition of CXCL1 by neutralizing antibody and specific shRNAs decreased CRC tumor growth. Highly elevated CXCL1 expression significantly correlated with decreased overall survival in stage IV CRC patients (hazard ratio 0.28; 95% CI 0.11-0.72). High CXCL1 expression is a poor prognostic biomarker in metastatic CRC. CXCL1 inhibition suppressed tumorigenic growth of KRAS mutant CRC cells.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 2%
Denmark 1 2%
Unknown 40 95%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 19%
Student > Ph. D. Student 8 19%
Researcher 5 12%
Student > Master 5 12%
Other 2 5%
Other 3 7%
Unknown 11 26%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 9 21%
Medicine and Dentistry 8 19%
Agricultural and Biological Sciences 6 14%
Immunology and Microbiology 3 7%
Psychology 1 2%
Other 3 7%
Unknown 12 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2022.
All research outputs
#2,772,081
of 23,257,423 outputs
Outputs from Journal of Translational Medicine
#445
of 4,095 outputs
Outputs of similar age
#36,250
of 264,911 outputs
Outputs of similar age from Journal of Translational Medicine
#8
of 99 outputs
Altmetric has tracked 23,257,423 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,095 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,911 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.